COX/5-LO-IN-1 - CAS 154355-75-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C16H15FN2O2S
Molecular Weight:
318.37
COA:
Inquire
Targets:
5-Lipoxygenase | COX
Description:
A dual inhibitor of cylooxygenase and 5-lipoxygenase
Synonyms:
Urea, N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propyn-1-yl]-N-hydroxy-; 1-[4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea
Storage:
Store in a cool and dry place (or refer to the Certificate of Analysis).
MSDS:
Inquire
Boiling Point:
506.7±60.0 ℃ at 760 Torr
Density:
1.37±0.1 g/cm3
InChIKey:
MMSNEKOTSJRTRI-UHFFFAOYSA-N
InChI:
1S/C16H15FN2O2S/c1-11(19(21)16(18)20)2-7-14-8-9-15(22-14)10-12-3-5-13(17)6-4-12/h3-6,8-9,11,21H,10H2,1H3,(H2,18,20)
Canonical SMILES:
CC(C#CC1=CC=C(S1)CC2=CC=C(C=C2)F)N(C(=O)N)O
1.Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers.
Wong SL;Drajesk J;Chang M;Lanni C;Witt G;Hansen R;Awni WM Clin Pharmacol Ther. 1998 Mar;63(3):324-31.
OBJECTIVE: ;This study evaluated the safety, pharmacokinetics and pharmacodynamics of ABT-761 [R(+)-N-[3-[5-(4-fluorophenylmethyl)-2-thienyl]-1- methyl-2-propynyl]-N-hydroxyurea], a new N-hydroxyurea analog.;METHODS: ;This was a randomized, double-blind, placebo-controlled, single- and multiple-dose (15-day) study of ABT-761 (50 to 200 mg/day) in healthy, nonsmoking adult male volunteers. The pharmacokinetics were evaluated by investigation of the time- and dose-dependent effects of ABT-761, and the pharmacologic selectivity of ABT-761 was evaluated based on calcium ionophore-stimulated leukotriene B4 (LTB4) and thromboxane B2 (TXB2) biosynthesis ex vivo in whole blood.;RESULTS: ;After single and multiple doses, mean observed time to reach maximum concentration values of ABT-761 ranged from 4.0 to 7.5 hours. Mean values for maximum concentration and area under the plasma concentration-time curve from 0 to 24 hours increased approximately linearly with dose. Mean terminal half-life and apparent volume of distribution during the terminal elimination phase of ABT-761 ranged from 15.4 to 17.8 hours and 69.5 to 78.9 L, respectively, and was dose independent. Steady state was reached on day 11 after multiple dosing.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related 5-Lipoxygenase Products


CAS 99464-64-9 Ampiroxicam

Ampiroxicam
(CAS: 99464-64-9)

Ampiroxicam is a nonselective cyclooxygenase inhibitor uesd as anti-inflammatory drug.

CAS 4079-26-9 PD 146176

PD 146176
(CAS: 4079-26-9)

PD 146176 is a specific, non-competitve 15-lipoxygenase (15-LOX) inhibitor (Ki = 197nM), without effect on 5-LOX, 12-LOX, COX-1 or COX-2 (IC50 = 0.54 μM for 15-...

CAS 59937-28-9 Malotilate

Malotilate
(CAS: 59937-28-9)

Malotilate, diisopropyl 1,3-dithiol-2-ylidenemalonate, is a drug used for the treatment of liver cirrhosis.

CAS 103-90-2 Acetaminophen

Acetaminophen
(CAS: 103-90-2)

A selective COX-2 inhibitor

CAS 170569-88-7 Mavacoxib

Mavacoxib
(CAS: 170569-88-7)

Mavacoxib, a pyrazol derivative, has been found to be a COX-2 Inhibitor that could be used in pain and inflammation therapy for dogs.

CAS 19210-12-9 Harpagoside

Harpagoside
(CAS: 19210-12-9)

Harpagoside, isolated from the Harpagophytum procumbens (Devil's Claw) root or Crophularia ningpoensis Hemsl (Figwort), inhibited lipopolysaccharide-induced mRN...

CAS 205654-37-1 CMI-392

CMI-392
(CAS: 205654-37-1)

CMI-392 is a dual antagonist of 5-lipoxygenese (IC50= 100 nM) and platelet-activating factor (PAF) receptor (IC50= 10 nM).

CAS 102271-49-8 PGS-IN-1

PGS-IN-1
(CAS: 102271-49-8)

PGS-IN-1 is a potent inhibitor of prostaglandin synthetase (PGS) (IC50= 0.28 μM) and also an inhibitor of 5-lipoxygenase (IC50= 1.05 μM).

Chemical Structure

CAS 154355-75-6 COX/5-LO-IN-1

Quick Inquiry

Verification code

Featured Items